# A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

> **NCT05662397** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **HotSpot Therapeutics, Inc** · enrollment: 77 (actual)

## Conditions studied

- Solid Tumor, Adult
- Relapsed Cancer
- Refractory Cancer

## Interventions

- **DRUG:** HST-1011
- **BIOLOGICAL:** Cemiplimab

## Key facts

- **NCT ID:** NCT05662397
- **Lead sponsor:** HotSpot Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662397, "A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05662397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*